ReviewiScience2025
Role of the circular RNAs/microRNA/messenger RNA axis in renal cell carcinoma: From gene regulation to metabolism and immunity.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Overlapping expression characteristics of ubiquitination-related genes in periodontitis and renal cell carcinoma: transcriptomic analysis and experimental validation.BMC oral health · 2026Article
- Hepatic-Differentiated Subpopulation in Clear Cell Renal Cell Carcinoma: A Multi-Omics Analysis of Tumors With Lymphovascular Invasion.Cancer medicine · 2026Article
- Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives.Clinical and experimental medicine · 2026Review
- Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulatingTranslational andrology and urology · 2025Article
- Dual-faced circRNAs: orchestrating immunosuppression and activation in the lung cancer microenvironment.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC), particularly clear cell RCC (ccRCC), has seen rising incidence and mortality rates. Early detection remains difficult due to nonspecific symptoms, often leading to diagnoses at advanced stages and unfavorable prognoses. Current treatments, including surgery, targeted therapies, and immunotherapies, face limitations such as adverse reactions, drug resistance, and immune evasion. This review discusses the role of circular RNAs (circRNAs) and their involvement in the circRNA/miRNA/mRNA axis during RCC progression. As competitive endogenous RNAs (ceRNAs), circRNAs regulate gene expression and cellular processes, including proliferation, metastasis, apoptosis, and drug resistance. Furthermore, we explore the impact of circRNAs on tumor metabolic reprogramming and their influence on the immune microenvironment. We also summarize the clinical prospects, challenges, and future directions in this field. A comprehensive understanding of these complex interactions may provide new insights into the diagnosis and treatment of RCC, ultimately overcoming existing challenges and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.